Status as of May 20, 2025	Please note • This is an **early draft of the program which is subject to changes** in both session topics and the schedule. As the content is developed updates will be posted. • We are excited to celebrate the **10th anniversary** of the EFSPI regulatory statistics meeting this year. To mark this milestone, we have planned a special commemoration on **Day 1** (tentative), which will reflect on the past and look forward to the future of this annual meeting. We will conclude the day with a **get-together featuring the traditional wine tasting**.

10th EFSPI Regulatory Statistics Workshop

10-12 September 2025

Basel Switzerland

Day 1: 10th September 2025, 08:30-17:00 (+2h wine tasting)

Time	**Presentation**
08:30 – 08:45 (15 min)	**Opening Remarks** Egbert Biesheuvel (EFSPI President, Viatris, NL)
08:45 – 10:15 (90 min)	**"Overture": Strategic Priorities in Pharmaceutical Statistics** Speakers will discuss 1. Regulatory priorities in Europe 2. Industry view on regulatory priorities in Europe Followed by a Q&A – bring your questions and thoughts about strategic priorities *Chairs: TBC* Talk 1: <*title*>, Kit Roes (Chair of MWP EMA, NL) Talk 2: <*title*>, <EFSPI Statistical Method Leader> (…, ..) Q&A with the audience, the speakers (and regulatory agency representatives from other regions)
10:15 – 10:45 (30 min)	Coffee break
10:45 – 12:30 (105 min)	**ICH E20 Guideline on "Adaptive Clinical Trials" – A Critical Discussion from Different Perspectives** Homework: To get most out of the session please read the ICH E20 draft guideline on Adaptive Clinical Trials currently on public consultation <*add link*> Discussants will pick and discuss one or two topics that they found the most thought-provoking. *Chairs: Khadija Rantell (MHRA, UK), Fredrik Öhrn (J&J, SE)* Talk 1: <*title/ICH guideline into*>, <speaker TBC>, (…, ..) Talk 2: <*title/discussant from academia*>, < speaker TBC>, (…, ..) Talk 3: <*title/discussant from industry*>, <speaker TBC>, (…, ..) Talk 4: <*title/discussant from regulatory*>, <speaker TBC>, (…, ..) Talk 5: <*title/ discussant from HTA*>, <speaker TBC>, (…, ..) Moderated panel discussion with the audience, the speakers and ICH E20 WG members
12:30 – 14:00 (90 min)	Lunch break and poster session: ESIGs and EFSPI Working Groups

14:00 – 15:30 (90 min)	**Characterizing the Effect of Treatment Using Hierarchical Composite Endpoints – Risks and Benefits of Win Statistics and Beyond** HCEs are proposed in several therapeutic areas with the intent to characterize the effect of treatment by combining different outcomes using Generalized Pairwise Comparisons (e.g. win statistics), Desirability of Outcome Ranking, or Ordinal Longitudinal Models for State Occupancies. Speakers from regulatory agencies as well as industry will critically discuss the need to address a well-defined clinical question of interest, pros and cons of the different approaches, and their role in regulatory decision making. *Chairs: Andreas Brandt (BfArM, DE), Patrick Schlömer (Bayer, DE), <…>* Talk 1: <*title*>, Henrik F Thomson (Novo Nordisk, DK) and Mickaël De Backer (UCB, BE) Talk 2: <*title*>, Lukas Aguirre Dávila (PEI, DE; SAWP member) Moderated panel discussion and Q&A with the audience and the speakers
15:30 – 16:00 (30 min)	Coffee break
16:00 – 17:00 (60 min)	**10th Anniversary of the EFSPI Regulatory Statistics Workshop** *Theme + Speakers TBC*
17:00 – 19:00	**Wine tasting** organised by Hans Ulrich Burger (Roche, CH) and Emmanuel Zuber (Independent consultant, CH)

Day 2: 11th September 2025, 09:00-17:30

Time	Presentation
09:00 – 11:00 (120 min)	**Short Topics**: **Present a problem on 2-3 slides and receive input from a panel of regulators** (20 mins per topic; only F2F presenters allowed) *Chairs: Elina Asikanius (fimea, MWP, FI), Kaspar Rufibach (Merck KgaA, CH)* Confirmed panelists: <TBC> (affiliations and country codes) Topic 1: < … > Topic 2: < … > Topic 3: < … > Topic 4: < … > Topic 5: < … > Topic 6: < … > Please send proposals by [date] to [e-mail] Note: You can submit a problem and, if selected, you can discuss it with a panel of highly esteemed regulators. Proposals should be sent to Vivian Lanius, Vivian.lanius@ucb.com, no later than 11 August 2025.
11:00 – 11:30 (30 min)	Coffee break

11:30 – 12:30 (60 min)	**From Black Box to Pandora's Box: Navigating AI in Clinical Trials** *Chairs: Jenny Devenport (Roche, CH), Florian Klinglmueller (AGES, MWP, AT)* Talk 1: <*title*>, <speaker, TBC>, (…, ..) Talk 2: <*title*>, <HTA representative / academia>, (…, ..) Talk 3: <*title*>, Chris Harbron (Roche, UK) Moderated panel discussion with the audience and the speakers
12:30 – 14:00 (90 min)	Lunch break
14:00 – 15:30 (90 min)	**Keeping it Real or Losing Control? Adventures in Target Trial Emulation** Goal: to explore how Target Trial Emulation (TTE) can improve transparency and methodological rigor when designing, evaluating, and assessing clinical trials incorporating observational data. Different stakeholders will gain insights into regulatory expectations, industry experiences, and how TTE enhances alignment and communication between regulators and pharmaceutical companies. This includes how TTE clarifies assumptions, addresses biases, and facilitates robust sensitivity analyses and evaluation criteria through structured links to randomized trials. *Chairs:* *Julie Jones (Novartis, CH), Florian Klinglmueller (AGES, MWP, AT), Pierre Mancini (Sanofi, FR)* Talk 1: <*title*>, Olaf Klungel (MWP, University of Utrecht, NL) Talk 2: <*title*>, <industry speaker, TBC> (…, ..) Talk 3: <*title*>, Angelika Geroldinger (AGES, AT) Facilitated Q&A with the audience, the speakers <and further discussants>
15:30 – 16:00 (30 min)	Coffee break
16:00 – 17:30 (90 min)	**From Trials to Target Populations: Extending Evidence for Decision-Making [TBC]** Speakers will discuss issues of transportability and generalisability *Chairs: Seamus Kent (ESHPM, NL), Anja Schiel (NoMA, MWP, NO; SAWP member)* Talk 1: <*title*>, <speaker> (…, ..) Talk 2: <*title*>, <speaker> (…, ..) Talk 3: <*title*>, <speaker> (…, ..) Q&A / panel discussion with the audience, the speakers <and further discussants>

Day 3: 12th September 2025, 09:00-12:10

Time	Presentation
08:30 – 10:00 (90 min)	**Bayesian Clinical Trial Designs in Drug Development** *Chairs: NN, NN* Talk 1: <*title*>, <speaker> (…, ..) Talk 2: <*title*>, Katharina Hees (PEI, DE) Moderated panel discussion with <list of panelists>, (.., ..) Q&A with the audience and the speakers
10:00 – 10:30 (30 min)	Coffee break
10:30 – 12:00 (90 min)	**How to Deal with Assumptions in Drug Development?** **What Insights Can We Gain from ICH M15?** *Chairs: Claudia Dallinger (Boehringer Ingelheim, DE), Rafael Sauter (Swissmedic, CH)* Talk 1: <*title*>, Flora Musuamba Tshinanu (University of Namur, MWP, BE; SAWP member) Talk 2: <*title*>, <speaker> (…, ..) Talk 3: <*title*>, Tobias Mielke (J&J, DE) Talk 4: <*title*>, <speaker> (…, ..) Q&A / panel discussion with the audience, the speakers <and further discussants>
12:00 – 12:10	**Closure**
12:10	Lunch

Confirmed posters:

ESIG/EFSPI Working Group	Title	Author(s)/Presenter(s)